📊 BRTX Key Takeaways
Investment Thesis
BioRestorative Therapies exhibits severe financial distress with massive operating losses (-$11.8M) against minimal revenue ($340.1K), indicating the company is burning cash at an unsustainable rate. With negative operating cash flow of -$8.4M, only $602.4K in cash reserves, and revenue declining 35.7% YoY, the company faces critical liquidity risk and potential insolvency without immediate capital injection or dramatic operational turnaround.
BRTX Strengths
- Exceptional gross margin of 93.5% suggests underlying product economics could be viable if revenue scales
- Moderate debt-to-equity ratio of 0.11x indicates limited financial leverage and lower bankruptcy risk from debt obligations
- Current ratio of 1.37x provides minimal short-term liquidity cushion above critical threshold
BRTX Risks
- Severe cash burn rate of -$8.4M operating cash flow against only $602.4K cash reserves indicates runway of approximately 2-3 months
- Collapsing revenue (-35.7% YoY) combined with fixed operating costs creates deteriorating unit economics and path to insolvency
- Massive negative profitability metrics (Operating Margin: -3476%, Net Margin: -3244%) demonstrate fundamental business model failure at current scale
- No insider buying activity in 90 days suggests lack of management confidence in company prospects
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Revenue stabilization and return to growth trajectory
- Operating expense reduction and path to operating cash flow breakeven
- Success of capital raising efforts to extend liquidity
BRTX Financial Metrics
💡 AI Analyst Insight
BioRestorative Therapies, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BRTX Profitability Ratios
BRTX vs Default Sector
How BioRestorative Therapies, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BRTX Balance Sheet & Liquidity
BRTX 5-Year Financial Trend
5-Year Trend Summary: BioRestorative Therapies, Inc.'s revenue has grown significantly by 208% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.47 indicates the company is currently unprofitable.
BRTX Growth Metrics (YoY)
BRTX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.8K | -$1.1M | $-0.13 |
| Q2 2025 | $89.1K | -$2.2M | $-0.30 |
| Q1 2025 | $25.0K | -$2.2M | $-0.33 |
| Q3 2024 | $30.7K | -$1.1M | $-0.13 |
| Q2 2024 | $64.5K | -$2.2M | $-0.50 |
| Q1 2024 | $31.3K | -$2.2M | $-0.33 |
| Q3 2023 | $29.0K | -$2.9M | $-0.64 |
| Q2 2023 | $64.5K | -$3.0M | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BRTX Capital Allocation
BRTX SEC Filings
Access official SEC EDGAR filings for BioRestorative Therapies, Inc. (CIK: 0001505497)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BRTX
What is the AI rating for BRTX?
BioRestorative Therapies, Inc. (BRTX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BRTX's key strengths?
Exceptional gross margin of 93.5% suggests underlying product economics could be viable if revenue scales. Moderate debt-to-equity ratio of 0.11x indicates limited financial leverage and lower bankruptcy risk from debt obligations.
What are the risks of investing in BRTX?
Severe cash burn rate of -$8.4M operating cash flow against only $602.4K cash reserves indicates runway of approximately 2-3 months. Collapsing revenue (-35.7% YoY) combined with fixed operating costs creates deteriorating unit economics and path to insolvency.
What is BRTX's revenue and growth?
BioRestorative Therapies, Inc. reported revenue of $340.1K.
Does BRTX pay dividends?
BioRestorative Therapies, Inc. does not currently pay dividends.
Where can I find BRTX SEC filings?
Official SEC filings for BioRestorative Therapies, Inc. (CIK: 0001505497) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BRTX's EPS?
BioRestorative Therapies, Inc. has a diluted EPS of $-1.26.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.